Kawasaki MATCH decision support for suspected Kawasaki disease
Official title: Kawasaki MATCH: A Clinical Decision Support Tool to Detect KD
Run by University of California, San Diego · NCT07291245 · Data updated 2026-11-12
This study will test a machine-learning tool called Kawasaki MATCH to help providers decide if febrile children might have Kawasaki disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Days to 17 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT07291245 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children with measured or subjective fever for >= 3 days (or infants < 6 months with >= 7 days of fever), at least one fever >= 38.0°C, one or more Kawasaki clinical features, and who require IV/phlebotomy are the ideal candidates.
✕Probably not a fit
Patients without fever or those who do not require blood testing, patients with immunodeficiency or on systemic immunosuppression/chemotherapy, and children seen outside the participating hospital are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
After laboratory evaluation, providers are randomized to follow usual care or to receive point-of-care recommendations from Kawasaki MATCH, a previously validated machine-learning clinical decision support tool. The trial measures the tool's diagnostic accuracy when used during routine care and records how it changes clinician actions such as additional testing or hospital admission. Eligible patients are children with multiple days of fever and one or more clinical features of Kawasaki disease (or infants under 6 months with prolonged fever) who require bloodwork. Study outcomes include prospective accuracy of the tool, changes in evaluation and admission decisions, and safety and feasibility of bedside use.
Why it matters
Potential benefit: If successful, Kawasaki MATCH could help clinicians identify Kawasaki disease earlier and make more consistent decisions about testing and hospital admission.
How similar studies have gone: Kawasaki MATCH has prior validation data showing promising diagnostic accuracy, but prospective, point-of-care testing of its impact on clinician decision-making is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Measured or subjective fever for \>= 3 calendar days * One measured fever \>= 38.0 C (home or in ED) * One or more clinical feature of Kawasaki Disease including: * Rash * Conjunctival injection * Oropharyngeal changes * Extremity changes (erythema, edema, desquamation) * Cervical adenopathy (\>=1.5cm) * Infants \< 6 months of age with \>= 7 days of fever eligible even if none of the above clinical features * Requires IV/phlebotomy for clinical evaluation Exclusion Criteria: * Congenital or Acquired Immune function * Genetic disorders * Current systemic steroid, immunosuppression, or chemotherapy treatment (not including inhaled steroids)
Where it's running
-
Rady Children's Hospital, San Diego
San Diego, California, United States Recruiting
Study contacts
- Study coordinator: Michael A Gardiner, MD
- Email: magardiner@health.ucsd.edu
- Phone: 949-310-4808
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Atorvastatin in Chinese children with Kawasaki disease and coronary artery abnormalities
This phase 3 study tests whether atorvastatin is safe and helpful for children with Kawasaki disease who have coronary artery abnormalities.
-
Cardiovascular health in children and young adults with chronic conditions
This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.
-
Analyzing Rivaroxaban in Chinese Children with Kawasaki Disease
This study is testing how well the blood thinner rivaroxaban works in children with Kawasaki disease who have serious heart problems.
-
Optimizing Rivaroxaban Dosing for Children with Giant Coronary Aneurysms After Kawasaki Disease
This study is testing a new way to dose a blood thinner called rivaroxaban for Chinese children with giant coronary aneurysms after Kawasaki disease to see if it helps prevent heart problems.
-
Observing Kawasaki disease in European and North Indian children
This study looks at children with Kawasaki disease to see if certain scoring systems can help identify those who don't respond to standard treatment, focusing on kids from Europe and North India.
-
Rivaroxaban for children over 2 with giant coronary artery aneurysms after Kawasaki disease
This trial will test whether rivaroxaban given with an antiplatelet medicine is a safe and practical alternative to warfarin for preventing clots in children aged 2 and older with giant coronary artery aneurysms after Kawasaki disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.